QGEN
QIAGEN NV
NYSE · Healthcare · Medical - Diagnostics & Research · NL
$43.33
−2.37%Year over year
Reported trailing growth
- Revenue
- +3.0%
- EBITDA
- +2.9%
- EBIT
- +13.6%
- EPS
- +14.0%
- Free cash flow
- -9.8%
- Operating cash flow
- -3.0%
Forward estimates
Based on analyst estimates
- Revenue
- +3.9%
- EBITDA
- +21.2%
- EPS
- +28.0%
Three-year CAGR
- Revenue
- -0.8%
- EBITDA
- -2.7%
- EBIT
- -0.7%
- Net income
- +0.1%
- EPS
- -0.6%
- Free cash flow
- -7.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026